Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Clinical Treatment and Management of Neuro-Ophthalmic Disease
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Treatment and Management of Neuro-Ophthalmic Disease

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: closed (26 December 2024) | Viewed by 2369

Special Issue Editors

Dr. Francisco J. Povedano-Montero

E-Mail Website
Guest Editor
Optometry and Vision Department, Complutense University of Madrid, Madrid, Spain
Interests: optometry; neuro-ophthalmic disease; glaucoma; retina; neuroscience
Special Issues, Collections and Topics in MDPI journals
Dr. Pilar Rojas Lozano

E-Mail Website
Guest Editor
Hospital General Universitario Gregorio Marañón de Madrid, Madrid, Spain
Interests: ophthalmology; neuroinflammation; neuroscience; neurodegeneration

Special Issue Information

Dear Colleagues,

We are pleased to announce that the Journal of Clinical Medicine is preparing a Special Issue dedicated to the "Clinical Treatment and Management of Neuro-Ophthalmic Disease". This Special Issue aims at gathering cutting-edge research, and comprehensive reviews in the field of neuro-ophthalmology.

We invite researchers, clinicians, and academics to contribute their original manuscripts that address various aspects of the diagnosis, treatment, and management of neuro-ophthalmic diseases. Topics of interest include, but are not limited to, advanced diagnosis, innovative therapies, surgical management, neuroprotection, visual rehabilitation, and case studies that shed light on unique approaches to patient management.

Manuscripts will be rigorously peer-reviewed to ensure the quality and relevance of the content. Acceptance will be based on originality, clinical significance, and research quality.

We look forward to your valuable contributions to this Special Issue and appreciate your commitment to advancing knowledge in the field of neuro-ophthalmology.

Dr. Francisco J. Povedano-Montero
Dr. Pilar Rojas Lozano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuro-ophthalmology
  • advanced diagnosis
  • nervous system manifestations
  • surgical management
  • neuroprotection
  • visual rehabilitation
  • clinical research
  • case studies
  • disease management
  • treatment advancements

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 230 KiB  
Article
Nonadherence to Cardiovascular Drugs Predicts Risk for Non-Arthritic Anterior Ischemic Optic Neuropathy: A Large-Scale National Study
by Anan Hammud, Yosef. S. Haviv, Eyal Walter, Nir Amitai, Tomer Kerman, Samuel Leeman and Erez Tsumi
J. Clin. Med. 2024, 13(16), 4670; https://doi.org/10.3390/jcm13164670 - 9 Aug 2024
Viewed by 1364
Abstract
Purpose: While patients with cardiovascular comorbidities are at a higher risk for the occurrence of non-arteritic anterior ischemic optic neuropathy (NAION), it is unclear whether adherence to medication results in risk reduction. The purpose of this study was to investigate whether nonadherence [...] Read more.
Purpose: While patients with cardiovascular comorbidities are at a higher risk for the occurrence of non-arteritic anterior ischemic optic neuropathy (NAION), it is unclear whether adherence to medication results in risk reduction. The purpose of this study was to investigate whether nonadherence to medical therapy for cardiovascular morbidity correlates with a higher risk for NAION when compared to patients with strict adherence. Methods: A retrospective case-control study was conducted among members of Clalit Health Services in Israel from 2001 to 2022. For each of the 757 NAION cases, three controls (totaling 2271 patients) were matched based on birth year and sex, with a propensity score analysis employed to adjust for a range of comorbidities. A patient was deemed nonadherent with medical treatment if their purchased quantity of medication was less than 60% of the prescribed annual dosage. Mixed models were used to evaluate exposure differences, and conditional logistic regression was applied, incorporating adjustments for socioeconomic status and ethnicity, to examine the impact of medication nonadherence on NAION risk. Results: A total of 3028 patients were included in the study; 757 patients with the diagnosis of NAION and 2271 in the matched control group. The average age of NAION patients was 69 ± 9 years and 55% were male. After adjustments for socioeconomic status and ethnicity, nonadherence to calcium channel blockers (CCBs) (odds ratio [OR]: 1.33, 95% confidence interval [CI]: 1.03–1.71) and anti-arrhythmic (OR: 5.67, 95% CI: 1.89–21.2) medications emerged as significant risk factors. Similarly, nonadherence to cardioprotective medications (OR: 1.46, 95% CI: 1.23–1.74) was also identified as a significant risk factor. Conclusions: Nonadherence to treatments for cardiovascular disease, specifically to medications known to improve prognosis, is associated with a higher risk for NAION. Full article
(This article belongs to the Special Issue Clinical Treatment and Management of Neuro-Ophthalmic Disease)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop